Epidemiology of the insulin resistance syndrome

被引：82

作者：

James B. Meigs

机构：

[1] General Medicine Division, Massachusetts General Hospital, Boston, MA 02114

来源：

Current Diabetes Reports | 2003年 / 3卷 / 1期

关键词：

Metformin; Troglitazone; Metabolic Risk Factor; Diabetes Prevention Program; Insulin Resistance Syndrome;

D O I：

10.1007/s11892-003-0057-2

中图分类号：

学科分类号：

摘要：

The insulin resistance syndrome consists of the co-occurrence of metabolic risk factors for type 2 diabetes and cardiovascular disease, including over-all obesity, central obesity, dyslipidemia (characterized by elevated levels of triglycerides and low levels of high-density lipoprotein cholesterol), hyperglycemia, and hypertension. Using criteria proposed by the National Cholesterol Education Program Adult Treatment Panel III, national survey data suggest the insulin resistance syndrome is very common, affecting about 24% of US adults aged greater than 20 years. The syndrome is more common in older people and in Mexican Americans, and will increase in prevalence as populations age and become more obese. Identification of the syndrome warrants aggressive interventions known to prevent type 2 diabetes and cardiovascular disease, including weight reduction, increased physical activity, and control of hypertension and dyslipidemia. Copyright © 2003 by Current Science Inc.

引用

页码：73 / 79

页数：6

共 50 条

[21]

Kekalainen P., Sarlund H., Pyorala K., Laakso M., Hyperinsulinemia cluster predicts the development of type 2 diabetes independent of a family history of diabetes, Diabetes Care, 22, pp. 86-92, (1999)

[22]

Lempiainen P., Mykkanen L., Pyorala K., Et al., Insulin resistance syndrome predicts coronary heart disease events in elderly nondiabetic men, Circulation, 100, pp. 123-128, (1999)

[23]

Pyorala M., Miettinen H., Halonen P., Et al., Insulin resistance syndrome predicts the risk of coronary heart disease and stroke in healthy middle-aged men: The 22-year follow-up results of the Helsinki Policemen Study, Arterioscler. Thromb. Vasc. Biol., 20, pp. 538-544, (2000)

[24]

Isomaa B., Almgren P., Tuomi T., Et al., Cardiovascular morbidity and mortality associated with the metabolic syndrome, Diabetes Care, 24, pp. 683-689, (2001)

[25]

Wilson P.W.F., D'Agostino R.B., Parise H., Meigs J.B., The metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus, Diabetes, 51, SUPPL. 1, (2002)

[26]

Balkau B., Charles M.A., Comment on the provisional report from the WHO consultation, Diabet. Med., 16, pp. 442-443, (1999)

[27]

Alberti K.G., Zimmet P.Z., Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation, Diabet. Med., 15, pp. 539-553, (1998)

[28]

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III), JAMA, 285, pp. 2486-2497, (2001)

[29]

Knowler W.C., Barrett-Connor E., Fowler S.E., Et al., Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin, N. Engl. J. Med., 346, pp. 393-403, (2002)

[30]

Tuomilehto J., Lindstrom J., Eriksson J.G., Et al., Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance, N. Engl. J. Med., 344, pp. 1343-1350, (2001)

← 1 2 3 4 5 →